03 Profile
Vital Signsby Bridgehead
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Diabetes
Robert Geho: no photograph is held, so the sector leader plate is shown instead.
Sector leader
Robert Geho
Co-founder and CEO of Diasome
1
0
Oct 2026Nov 2026to date
1
press citation on 1 topic since 18 Oct 2026 · last quoted 18 Oct 2026
02 Quoted on · 1 of 29 topics
Robert Geho: key facts
- Kind of voice
- Sector leader
- Role
- Co-founder and CEO of Diasome
- Quoted on
- Diabetes
- Tracked press citations
- 1
- Most recently quoted
- 18 Oct 2026
04 The signal · where Robert Geho sits on diabetes
Ranked 45= of 100 voices quoted in the press on diabetes, level with 55 others on 1 citation.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Douglas TwenefourClinicianHead of Clinical, Diabetes UK11 - 2
Helen KnightRegulatorDirector of Medicines Evaluation, National Institute for Health and Care Excellence (NICE)9 - 3
Parth NarendranAcademicProfessor of Diabetes Medicine; Honorary Consultant Physician (leads the Type 1 Diabetes clinical service at the Queen Elizabeth Hospital Birmingham), University of Birmingham7 - 45=Sufyan HussainClinicianconsultant diabetes physician at Guy's and St Thomas' NHS Foundation Trust and King's College London1
- 45=Andrea SanabriaClinicianDr, interim director of Public Health1
- 45=Robert GehoSector leaderCo-founder and CEO of Diasome1
- 45=Juan Carlos Bazo-AlvarezClinicianDr, from the department of epidemiology and health at University College London (UCL), one of the researchers on the study1
- 45=Zoe KolokotroniClinician1
Showing the leaders and the ranks around 45=, of 100 voices · See every voice on the topic →
05 On the record · press
What Robert Geho has said
By outlet · linked articles
- genengnews.com1
Where Robert Geho has been quoted
- 01Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Datagenengnews.com · 18 Oct 2026
Verbatim
“Either subcutaneously or via oral administration, we're able to preferentially deliver enough of those payloads into the liver and the portal vein that feeds the liver to basically mimic the endogenous release of those materials.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- First UK patient treated with NICE approved TeplizumabUniversity of Birmingham
- Branding update for insulin pensDiabetes Research & Wellness Foundation
- DRWF Events: Register now for Diabetes: A Whole Life BlueprintDiabetes Research & Wellness Foundation
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 19 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.